2,5-Dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine

Catalog No. :
ACXOYJ530
CAS No. :
1180557-62-3
Molecular Formula :
C12H19BN2O2
Molecular Weight :
234.11

IUPAC Name:2,5-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine

2,5-Dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,5-Dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
IUPAC Name2,5-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
Molecular FormulaC12H19BN2O2
Molecular Weight234.11
SMILESCC1(C)C(C)(C)OB(C2=NC(C)=CN=C2C)O1
InChI KeyIQSZGXSHNMYRLS-UHFFFAOYSA-N
Synonym3,6-dimethylpyrazin-2-ylboronic acid pinacol ester;2,5-Dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine;Pyrazine, 2,5-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1180557-62-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACXOYJ530 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACCJPN083 route compound structure diagram
    ACCJPN08395-89-6 In Stock
  4. Then
  5. ACXOYJ530 route product structure diagram
    ACXOYJ5301180557-62-3
Inquiry

2. ACXOYJ530 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXOYJ530 route product structure diagram
    ACXOYJ5301180557-62-3
Inquiry

Comments (0)